Department of Ophthalmology and Visual Sciences, Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA.
Am J Ophthalmol. 2010 Jan;149(1):10-17. doi: 10.1016/j.ajo.2009.08.038.
To review the current state of molecular genetic testing as it relates to pediatric ophthalmology and to discuss its uses.
Review and evaluation of available molecular genetic testing.
Literature review and discussion of testing in practice based on the authors' clinical and laboratory experience.
Fee-for-service testing for many genetic eye diseases now is available. A report is always generated for fee-for-service testing. Detection of DNA variants in genes known to cause eye disease must be interpreted taking into account the variability of the human genome, the presence of benign variants (polymorphisms), and the carrier frequency of recessive alleles. Negative results in genetic testing are helpful in some disorders for which most of the causative genes are known and many disease-causing variants have already been reported, but are less helpful in those that currently have many undiscovered causative genes or novel mutations. Research-based testing also is available, but does not always yield a result. Patients with RPE65-associated Leber congenital amaurosis may be eligible for the current gene therapy trial. Patients with a variety of disorders may benefit from improved surveillance if their genetic diagnosis is known.
Entry into the genetic testing system often is via the patient's ophthalmologist. Collaboration with geneticists and genetic counselors, use of web sites to keep up with the ever-changing availability and detection rates, and knowledge of clinical trials, when combined with excellent clinical diagnosis, can improve diagnosis and allow eligible patients to participate in treatment trials.
回顾与小儿眼科学相关的分子遗传学检测现状,并讨论其用途。
对现有分子遗传学检测进行回顾和评估。
根据作者的临床和实验室经验,进行文献回顾和实践中检测的讨论。
现在可以对许多遗传性眼病进行收费服务检测。收费服务检测总会生成一份报告。在检测已知导致眼部疾病的基因中的 DNA 变体时,必须考虑到人类基因组的可变性、良性变体(多态性)的存在以及隐性等位基因的携带者频率。在大多数致病基因已知且已经报道了许多致病变体的遗传疾病中,基因检测的阴性结果有助于诊断,但在目前存在许多未发现的致病基因或新突变的疾病中,其帮助较小。研究型检测也可提供,但并不总是能得出结果。具有 RPE65 相关莱伯先天性黑矇的患者可能有资格参加当前的基因治疗试验。如果已知遗传诊断,患有各种疾病的患者可能会从更好的监测中受益。
进入遗传检测系统通常是通过患者的眼科医生。与遗传学家和遗传咨询师合作,利用网站了解不断变化的可用性和检测率,并了解临床试验,结合出色的临床诊断,可以改善诊断,并使符合条件的患者能够参与治疗试验。